Viz.ai announced today that it received CE mark approval for its flagship Viz LVO AI-based stroke care software platform.
San Francisco–based Viz.ai developed Viz LVO to use AI to automatically detect suspected large vessel occlusion (LVO) strokes on computed tomography angiography (CTA) imaging. Once the platform detects stroke, it directly alerts on-call stroke specialists about potentially treatable patients in a standalone or multi-hospital network, according to a news release.
The company touts its platform as capable of synchronizing stroke care, decreasing time to treatment and providing overall improvement to patient outcomes.
A recent, real-world, multi-center study using the platform found that median time-to-notification clocked at five minutes and 45 seconds across all sites using Viz LVO. The platform achieved 96% sensitivity and 94% specificity in identifying LVOs in 2,544 consecutive patients from 139 hospitals.
“Minutes matter when you’re having a stroke, which is why Viz.ai is dedicated to reducing time to treatment and improving patient outcomes through improved care coordination,” Viz.ai co-founder & CEO Chris Mansi said in the release. “The CE Mark allows us to bring our leading AI software to the EU, significantly expanding the number of patients we can help get access to life-saving therapy.”
In March of this year, Viz.ai announced that it raised $71 million in a Series C financing round. That round brought the company’s total funding to over $150 million, as Viz.ai raised a $50 million Series B in October 2019 and it reeled in $21 million in a Series A in July 2018.